CHA Biotech saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of CHA Biotech’s patent filings and grants. Buy the databook here.
CHA Biotech has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 50% of grants. The South Korea(KR), World Intellectual Property Organization(WIPO), and European Patent Office(EPO) patent Office are among the top ten patent offices where CHA Biotech is filings its patents. Among the top granted patent authorities, CHA Biotech has 50% of its grants in European Patent Office(EPO) and 50% in South Korea(KR).
Roche and Johnson & Johnson could be the strongest competitors for CHA Biotech
Patents related to cell & gene therapy lead CHA Biotech's portfolio
CHA Biotech has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Lung cancer related patents lead CHA Biotech portfolio followed by pancreatic cancer, and pain
CHA Biotech has highest number of patents in lung cancer followed by pancreatic cancer, pain, skin inflammation, and hypopituitarism.
For comprehensive analysis of CHA Biotech's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.